Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages

  Baraniskin, Alexander ^a,b   Nöpel Dünnebacke, Stefanie ^a,b   Ahrens, Maike ^a   Jensen, Steffen Grann ^c   Zöllner, Hannah ^a   Maghnouj, Abdelouahid ^a   Wos, Alexandra ^a   Mayerle, Julia ^d   Munding, Johanna ^a   Kost, Dennis ^a   Reinacher Schick, Anke ^b   Liffers, Sven ^a   Schroers, Roland ^b   Chromik, Ansgar M ^e   Meyer, Helmut E ^a   Uhl, Waldemar ^e   Klein Scory, Susanne ^b   Weiss, Frank U ^d   Stephan, Christian ^a   Schwarte Waldhoff, Irmgard ^b   Lerch, Markus M ^d   Tannapfel, Andrea ^a   Schmiegel, Wolff ^b   Andersen, Claus Lindbjerg ^c   Hahn, Stephan A ^a   more..

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

Author keywords

carcinoma; colorectal; diagnosis; hsa miR 1246; pancreatic ductal adenocarcinoma; RNU2 1; serum; U2 snRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1246; SMALL NUCLEAR RNA; U2 SMALL NUCLEAR RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; ASSAY; BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER TRANSPLANTATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA STABILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; AREA UNDER CURVE; BASE SEQUENCE; COLORECTAL NEOPLASMS; HUMANS; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RNA STABILITY; RNA, SMALL NUCLEAR; ROC CURVE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84869491009     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27791     Document Type: Article

References (46)

1. DiMagno EP, Reber HA, Tempero MA,. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999; 117: 1464-84.
2. Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34: 436-43.
3. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386-92.
4. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 487-91.
5. Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-16.
6. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
7. Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102: 89-95.
8. Brenner H, Hoffmeister M, Brenner G, et al. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer 2009; 45: 2027-33.
9. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
10. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. JAMA 1993; 269: 1262-7.
11. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-18.
12. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-33.
13. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-8.
14. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-33.
15. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38: 7248-59.
16. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
17. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
18. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
19. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
20. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa) 2009; 2: 807-13.
21. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
22. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010; 3: 109-13.
23. Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105: 1733-40.
24. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-80.
25. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6: e17745.
26. Laconti JJ, Shivapurkar N, Preet A, et al. Tissue and serum microRNAs in the Kras transgenic animal model and in patients with pancreatic cancer. PLoS One 2011; 6: e20687.
27. Liu J, Gao J, Du Y, Li Z, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012; 131: 683-91.
28. Li A, Omura N, Hong S-M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-37.
29. Keller A, Leidinger P, Bauer A, et al. Toward the blood-borne miRNome of human diseases. Nat Methods 2011; 8: 841-3.
30. Liao J, Yu L, Mei Y, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer 2010; 9: 198.
31. Kramer A,. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem 1996; 65: 367-409.
32. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6.
33. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New Engl J Med 2011; 365: 1384-95.
34. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 1995; 57: 289-300.
35. Perkins NJ, Schisterman EF,. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006; 163: 670-5.
36. Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515.
37. Zhang Y, Liao JM, Zeng SX, et al. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep 2011; 12: 811-17.
38. Lee LW, Zhang S, Etheridge A, et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 2010; 16: 2170-80.
39. Halicka HD, Bedner E, Darzynkiewicz Z,. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000; 260: 248-56.
40. Biggiogera M, Bottone MG, Martin TE, et al. Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes. Exp Cell Res 1997; 234: 512-20.
41. Kiss T,. Biogenesis of small nuclear RNPs. J Cell Sci 2004; 117: 5949-51.
42. Langenberger D, Bartschat S, Hertel J, et al. "MicroRNA or not microRNA?" Lecture Notes in Computer Science. Heidelberg: Springer, 2011. p 1-9.
43. Guo L, Liang T, Gu W, et al. Cross-Mapping events in miRNAs reveal potential miRNA-mimics and evolutionary implications. PLoS One 2011; 6: e20517.
44. Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007; 141: 67-75.
45. Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009; 6: 281-95.
46. StatXact 2001. StatXact 5 for Windows, user manual. Cambridge, MA: CYTEL Software Corporation, 2001